|From: luvb2b (Rep: 2098) reply to luvb2b||Date: 03/26/2019 10:45|
|Forum: Aldeyra Therapeutics, Inc - Msg #36||Thread #674072366 (Rec: 0) |
|here's the link to the original allergan pr, they mention 25m patient population for dry-eye.|
there was another recent deal between bausch & lomb and mimetogen to option a drug in development. terms were not disclosed, but here again they were saying 2.5b annual market for dry-eye. https://www.oraclinical.com/resource/bausch-lomb-acquires-option-to-license-new-compound-to-treat-dry-eye-syndrome-des/
aldx trial results were not for dry-eye specifically, but there's some overlap between that and allergic conjunctivitis that the aldx trial was for.
the aldx presentation mentions they are the first successful p3 trial in some time, and they had a very high relief of symptom response (2+ points on the scale, which they claim is first seen in a while). another highlight they claim is a novel mechanism of action. there are several other studies they need to do to reach approval so it's not "the" final p3 trial. but certainly the speed at which they are able to enroll and complete trials and their cash balance says they should be funded adequately (offering completed on the last super-spike after phase 2b results.
some additional notes from the 10k
There are approximately 20 million dry eye disease patients in the United States, yet only two drugs are approved for dry eye disease treatment, cyclosporine (0.05% as Restasis® or 0.09% as Cequa®) and lifitegrast (5% as Xiidra®). The activity of both drugs has been observed to be minimal or lacking in the majority of patients, and weeks or months of treatment may be required to achieve even modest clinical benefit.
There are approximately 100 million patients in the United States with allergic conjunctivitis, and we estimate that up to 30 million of such allergic conjunctivitis patients do not respond adequately to, or are dissatisfied with, topical antihistamines, the current standard of care. A primary reason for dissatisfaction with antihistamines appears to be lack of durable activity, which may be due to the fact that histamine is only one of the biological mediators of the disease, and the fact that increased histamine levels persist for only 10 to 20 minutes following allergen exposure.
Many patients manifest symptoms of both dry eye disease and allergic conjunctivitis, and differential diagnosis can be challenging for physicians. Approximately half of dry eye patients complain of itching, which is generally considered the result of allergy, and approximately half of allergic conjunctivitis patients complain of dryness, which is generally considered the result of dry eye disease. There are currently no United States Food and Drug Administration (FDA)-approved products that are indicated to treat both dry eye disease and allergic conjunctivitis. Neither cyclosporine nor lifitegrast have been approved for use in patients with allergic conjunctivitis, and antihistamines are known to exacerbate ocular dryness. Thus, with the possible exception of topical corticosteroids (discussed below), we believe that no currently available drug for dry eye disease or allergic conjunctivitis is likely to be effective for the treatment of patients who experience symptoms of both diseases.
aldx has a bunch of other programs advancing on this rasp anti-inflammatory platform as well.
so netting 95m of cash on the balance sheet, no debt w/ 27.5m shares outstanding around $11, the valuation given here is $300m for the whole co, and $205m net of cash. it just seems far too low given past deals, the size of the market, and the upside of dry-eye and other product candidates.
"There are those who market trades, and there are those who trade markets.
There are those who follow marketers, and those who follow markets.
The marketers feast on their followers; the traders feast on the markets." -luvb2b
***Disclaimer & Disclosure***: I make no guarantee as to the accuracy or validity of information in this message. Messages posted reflect my own opinions and/or those of others, and are posted for entertainment purposes only. My messages should not be construed as investment advice. Always make investment decisions in consultation with your own financial advisor. Daytrading is not suitable for everyone. You trade at your own risk. Daytrading involves considerable risk and could result in significant losses, including losses in excess of invested capital. Any information posted here is meant for entertainment purposes only and should not be assumed to be accurate. It is expected that the readers of this information do their own research and due diligence when making trading or investment decisions. I may have long or short positions in any of the stocks that are mentioned, and these positions may change at any time.
| Reply to luvb2b - Msg #2779927 - 03/26/2019 10:23|
listening to morning presentation for aldx. it sounds like there is substantial upside due to large patient populations and lack of recent advances in therapy. they're talking about 30m affected in the usa alone. i'm sure that there won't be 30m consumers of the drug, but just saying that there is a large patient population that is somewhat underserved by existing therapies.
a few years ago allergan acquired an in-development dry eye program for 125m. aldx will be starting a phase 3 trial for dry eye first half of this year and current market cap is under 300m with 100m in cash. just saying this does not seem properly valued.